RxDoctor Payments Data

Ellis Christian, MD

Interventional Cardiology · Fort Pierce, FLNPI 1376898122

Payments from drug & device makers

$5,002in general payments, 2019–2025

Across 154 payments — averaging $32.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Medtronic$760
  • Cardiovascular Systems Inc.$424
  • Kestra Medical Technology Services, Inc.$271
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$258
  • Astellas Pharma US Inc$252
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$2024%
  • Food & beverage$4,64293%
  • Education$1142%
  • Other$441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,002 in reported general payments places this provider in the 30th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$203,948
Medicare patients
448
Services billed
1,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban59$66,074
EntrestoSacubitril/Valsartan31$39,603
XareltoRivaroxaban15$22,788
BrilintaTicagrelor29$18,953
Prasugrel Hcl26$1,206
Atorvastatin Calcium88$1,162
Bumetanide14$1,021
Amlodipine Besylate136$818
Metoprolol Succinate54$666
Isosorbide Mononitrate ErIsosorbide Mononitrate48$548
Rosuvastatin Calcium27$425
Carvedilol46$413
ClopidogrelClopidogrel Bisulfate27$333
Hydrochlorothiazide33$326
Losartan Potassium30$292

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$189$66,07459 claims
NovartisEntresto$105$39,60331 claims
Johnson & JohnsonXarelto$205$22,78815 claims
AstraZenecaBrilinta$55$18,95329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Fort Pierce

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →